Imaging in Post-COVID Lung Disease: Does F-FDG PET/CT Have the Key?
(2022) The Journal of Nuclear Medicine — Vol. 63, n° 2, p. 268-269 (2022)
Files
Imaginginpost-Covidlungdisease.pdf
Open Access - Adobe PDF
- 445.13 KB
Details
- Authors
- Abstract
- (en) In this issue of The Journal of Nuclear Medicine, Thornton et al. present 18F-FDG PET/CT data obtained on coronavirus disease 2019 (COVID-19) patients at several disease stages (1). The study includes predominantly oncology patients in whom the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection was not known before the PET/CT procedure (n = 32), as well as 18 patients with known infection and persistent shortness of breath 28 d after the onset of disease and who were previously admitted to the hospital for oxygen therapy. The latter group was categorized as potential post–COVID-19 lung disease (PCLD) (2). In this PCLD group, half the patients had ongoing corticosteroid treatment. Although retrospective, this study triggers an interesting discussion on the potential role of 18F-FDG PET/CT in patients with late COVID-19 infection. [...]
- Affiliations
Citations
Gheysens, O., Belkhir, L., & Jamar, F. (2022). Imaging in Post-COVID Lung Disease: Does F-FDG PET/CT Have the Key? The Journal of Nuclear Medicine, 63(2), 268-269. https://doi.org/10.2967/jnumed.121.263166 (Original work published 2022)